Background: Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses. We hypothesised that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients. Methods: We conducted an international, randomised clinical trial testing the effects of intraoperative administration of ketamine [0.5 mg kg À1 (Lo-K) or 1.0 mg kg À1 (Hi-K)] vs control [saline placebo (P)] in patients !60 yr old undergoing major
Results: There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14. 7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference ¼ e2.7%; 95% confidence interval (CI), 5.0% to e9.4%; P¼0.446]. Of the total cohort, 9.6% (64/670; 95% CI, 7.6e12.0%) had symptoms suggestive of depression before operation, which increased to 16.6% (84/505; 95% CI, 13.6e20.1%) on POD3, and decreased to 11.9% (47/395; 95% CI, 9.1e15.5%) on POD30. Of the patients with depressive symptoms on POD3 and POD30, 51% and 49%, respectively, had no prior history of depression or depressive symptoms. Conclusions: Major surgery is associated with new-onset symptoms suggestive of depression in patients !60 yr old. Intraoperative administration of subanaesthetic ketamine does not appear to prevent or improve depressive symptoms. Clinical trials registration: NCT01690988.
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Editor's key points
Single subanaesthetic doses of i.v. ketamine may significantly improve symptoms in psychiatric patients with major depression. In patients undergoing major surgery, postoperative depressive symptoms are common. The authors studied the effect of a single intraoperative dose of ketamine on postoperative depressive symptoms in patients 60 years and older. New onset postoperative depressive symptoms were common but were not prevented by a single intraoperative dose ketamine.
Ketamine is a general anaesthetic that has been in clinical use for more than 50 yr and has also been tested as a treatment for depression. Meta-analyses of randomised controlled trials provide strong evidence that subanaesthetic ketamine is efficacious as a rapid-acting anti-depressant in unipolar and bipolar major depression. 1e6 The mechanism of ketamine's anti-depressant effects are unclear, but there is evidence suggesting that ketamine can reverse synaptic dysfunction induced by stress. 7 This raises the possibility that intraoperative administration of ketamine might improve postoperative mood and enhance resilience in the setting of surgical stress. Depressive symptoms are a known complication of major surgery and are associated with a number of health sequelae, including impaired functional recovery, suicidal ideation, and even mortality. 8, 9 Furthermore, postoperative depressive symptoms are not necessarily predictable based on past medical or psychiatric history. 10, 11 Thus, preventing depressive symptoms after surgery is a public health imperative and the intraoperative administration of ketamine is, in principle, an attractive candidate intervention. However, it is unclear if administration of ketamine in the perioperative period can prevent the development of depressive symptoms, a distinct intervention compared with the treatment of refractory depression in the non-surgical population. In a randomised controlled trial of depressed patients (n¼70) undergoing surgery, inducing general anaesthesia with propofol, ketamine, and fentanyl compared with propofol and fentanyl alone was associated with a reduced Hamilton Depression Rating on the first postoperative day (POD1). 12 A randomised controlled trial in healthy patients (n¼120) concluded that ketamine could mitigate depressive symptoms, as assessed by the Patient Health Questionnaire 9, after orthopaedic surgery. 13 Serum levels of brain-derived neurotrophic factor were increased in the ketamine-treated group, which is important because insufficient levels of this trophic factor seem to be mechanistically relevant to postoperative depressive symptoms. 9 Not all studies of ketamine and postoperative depressive symptoms have revealed therapeutic benefit. Intraoperative administration of subanaesthetic ketamine did not prevent postpartum depression in a randomised controlled trial of parturients undergoing Caesarean section (n¼330), 14 although the pathophysiology of this condition is likely distinct as compared with that of a major depressive disorder or depressive symptoms after non-obstetric surgery. Ketamine has also been explored as an adjunct to electroconvulsive therapy that could possibly mitigate adverse cognitive outcomes and improve therapeutic efficacy, but a multicentre trial testing this possibility did not find strong evidence of benefit. 15 Before concluding that ketamine is efficacious as an anaesthetic adjunct that improves postoperative depressive symptoms, a large, more generalisable study is required. Based on the recent meta-analyses supporting the antidepressant effects of ketamine and the evidence suggesting that ketamine might mitigate depressive symptoms in nonobstetric surgical patients, we hypothesised that intraoperative administration of subanaesthetic ketamine would prevent or mitigate postoperative depressive symptoms in patients undergoing major cardiac and non-cardiac surgery. In order to test these hypotheses, we conducted a prespecified analysis of the Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study, which was a multicentre, international, double-blind, randomised clinical trial that compared two doses of subanaesthetic ketamine with placebo for the prevention of postoperative delirium and pain.
Methods
Full methodological details of the PODCAST trial can be found in a published protocol, 16 and results can be found in the primary article reporting the study. 17 We conducted the trial at 10 
Patient population
Patients were included if they were !60 yr old, competent to provide informed consent, and undergoing major open cardiac or non-cardiac surgeries under general anaesthesia. Exclusion criteria included allergy to ketamine; patients for whom a significant elevation of blood pressure would constitute a serious hazard; patients with drug misuse history; patients taking anti-psychotic medications; and patients with a weight outside the range of 50e200 kg.
Interventions
PODCAST was a pragmatic trial, and decisions about anaesthetic technique, with the exception of instructions not to administer ketamine, were at the discretion of the anaesthesiology team assigned to each patient. After induction of general anaesthesia and before surgical incision, a dose of 0.5 mg kg À1 (Lo-K) or 1 mg kg À1 (Hi-K) ketamine or an equivalent volume of normal saline placebo (P), was injected via a reliable i.v. catheter. The typical anti-depressant dose of ketamine is 0.5 mg kg À1 , administered over 40 min in the awake patient.
7
Randomisation and blinding
Subjects were block-randomised by the hospital pharmacy departments in groups of 15 (1:1:1 ratio for Lo-K, Hi-K, and P groups). The random assignment was concealed from patients, anaesthesia clinicians caring for the patients, study team, and other trial staff. Codes were held by the hospital pharmacies, which dispensed the medication and maintained blinding until the primary analysis was completed.
Outcomes
This prespecified secondary analysis focused on data related to symptoms suggestive of depression and severity of depressive symptoms. The preoperative Patient Health Questionnaire 8 (PHQ-8) scale for depressive symptoms was used to classify the study sample into the categories of 'symptoms suggestive of depression' and 'without symptoms suggestive of depression'. The range of this scale is 0e24, and a standard threshold score of 10 or higher 18 was used to dichotomise patients into these two groups. It is important to note that meeting this PHQ-8 score criterion does not constitute a formal diagnosis of major depression. Rather, it is a screening tool and psychiatric evaluation is required for a definitive determination. The PHQ-8 was also used to assess severity of depressive symptoms before surgery, on POD3, and at approximately 1 month after surgery (POD30). Additionally, patients were screened for functional independence using the Barthel Index of Activities of Daily Living and asked whether they had a history of obstructive sleep apnoea. They were also asked about any falls they had experienced in the 6 months before surgery. Comorbid conditions, including lifetime history of major depression and the components of the Charlson Comorbidity Index, were extracted from patient medical records.
Statistical analysis
The primary hypotheses to be tested in this study were that subanaesthetic ketamine prevents postoperative depression and improves depressive symptoms at POD3, which would occur within the biologically plausible timeframe of ketamine's anti-depressant actions. 19 The PHQ-8 scores at POD3
and POD30 were used as continuous measures to: (1) test the effect of intraoperative ketamine on depressive symptoms; and (2) identify potential preoperative predictors of postoperative depression severity at POD30. The post hoc assessments of power for this study were based on a sample size of 600 patients, which was the estimated number needed to test the primary hypothesis of the original PODCAST trial (i.e. that intraoperative ketamine decreases the incidence of postoperative delirium). 17 For the current study, 15% of the target population (older adults undergoing major surgery) was estimated to suffer from early postoperative depression, and the minimum clinically important difference in the percentage of patients with symptoms suggestive of postoperative depression was assumed to be 5%. Based on these assumptions, a study with 400 patients in the combined ketamine groups (Lo-K plus Hi-K) and 200 in the placebo control group would only have power ranging from approximately 18% (with a twosided alpha <0.005) to 50% (with a two-sided alpha <0.05) to detect a 5% reduction in symptoms suggestive of depression. In contrast, the study would have been more appropriately powered to detect an effect of ketamine on depressive symptoms. The minimum clinically important difference in the PHQ-8 scores was assumed to be 1, and the estimated standard deviation for PHQ-8 scores was 4 (yielding a modest effect size of 0.25). Based on these assumptions, a study with 400 patients in the combined ketamine groups (Lo-K plus Hi-K) and 200 in the placebo control group would have power ranging from approximately 50% (with a two-sided alpha <0.005) to 80% (with a two-sided alpha <0.05) to detect a difference in POD3 PHQ-8 scores of 1 between the groups. These post hoc power calculations were done using G-Power software. Although the value of post hoc power calculation is controversial, 95% confidence intervals (CI) are presented as indicators of precision. We conducted unadjusted analyses using appropriate tests (e.g. Pearson's c 2 test and ManneWhitney U-test) to compare patient preoperative characteristics and postoperative PHQ-8 scores (at POD3 and POD30) between patients with and without preoperative symptoms suggestive of depression. For the primary outcome assessments of this study, we compared: (1) the proportion of patients with symptoms suggestive of depression in the combined ketamine groups and the control group with Fisher's exact test, with Newcombe's method to estimate 95% CI; and (2) PHQ-8 scores at POD3 between the combined ketamine groups and the control group with the ManneWhitney U-test, with the HodgeseLehmann approach to calculate the 95% CI for the difference between medians. We also used nonparametric ANOVA tests to compare postoperative PHQ-8 scores across the three PODCAST intervention groups (Lo-K, Hi-K, and P) at POD3 and POD30.
We conducted multivariable linear regression analyses to identify preoperative variables and surgery type that were independently associated with the severity of depressive symptoms at POD30. Potential predictors, selected a priori for inclusion in these models, were drawn from patient characteristics (sex, age, education level, marital status), health conditions (BMI, number of comorbidities, history of obstructive sleep apnoea), health behaviour (alcohol use), level of functionality (Barthel Index of Activities of Daily Living), type of surgery performed (cardiac vs non-cardiac), depression status (history of major depression and preoperative depressive symptoms), and the three study interventions (Lo-K, Hi-K, and P).
As there were many patients with missing PHQ-8 data elements at POD3 (165 missing) and POD30 (375 missing), we conducted post hoc sensitivity analyses to determine whether any of the findings would be altered with these missing data elements imputed. Our imputation approach was to carry forward PHQ-8 data elements (answered questions) from the most recent available questionnaire. By convention, statistical significance was based on a two-sided P value <0.05. All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC, USA).
Results

Study patient characteristics
We analysed data from 670 patients (Fig. 1) . Tables 1 and 2 show the patients' preoperative characteristics according to the three study groups. The cohort was also divided into those who had preoperative symptoms suggestive of depression and those without; patients who had a lifetime history of major depressive disorder were more likely to have preoperative symptoms suggestive of depression (P¼0.01). Supplementary   Tables S1 and S2 show the characteristics of surgical patients with or without preoperative symptoms suggestive of depression. Before the surgery, patients with symptoms suggestive of depression were more likely to be female, have a lower Barthel Index, report more falls (among patients who experienced falls), and report less alcohol use.
Effects of ketamine on postoperative depressive symptoms
There was no significant difference in the proportion of patients with symptoms suggestive of depression between the placebo [(23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups on POD3 (difference¼e2.7%; 95% CI, 5.0% to e9.4%; P¼0.446) ( Table 3) . Similarly, there was no significant difference in the severity of depressive symptoms between the placebo and combined ketamine groups at POD3 (median difference¼0; 95% CI, e1.0 to 1.0; P¼0.773) or POD30 (difference¼0; 95% CI, 0.0e1.0, P¼0.271). These findings were not altered with the sensitivity analysis (Supplementary Table S3 ). There was also no significant difference (P¼0.712) across the three groups (P, Lo-K, Hi-K) in depressive symptoms on POD3 (Fig. 2) . Likewise, there were no significant differences with the sensitivity analysis ( Supplementary Fig. S1 ). There was, however, a significant difference in median depressive symptoms across the three groups (P¼0.021) at POD30, but this difference was not significant (P¼0.321) after sensitivity analysis (i.e. imputation of missing PHQ8 results; see Supplementary Table S4 ).
Preoperative and postoperative depressive symptoms
Approximately 9.6% (64/670; 95% CI, 7.6e12.0%) of patients had symptoms suggestive of depression before operation, which increased to 16.6% (84/505; 95% CI, 13.6e20.1%) at POD3 and decreased to 11.9% (47/395; 95% CI, 9.1e15.5%) by POD30 ( Fig. 3 and Supplementary Fig. S2 ). Only six patients had the same PHQ-8 score (>10) at baseline and POD3, suggesting that depressive symptoms detected after the operation were not solely attributable to preoperative symptomatology. By the CochraneArmitage test, there was a significant overall increase in depressive symptoms among all patients over time (P<0.0001). Patients with a lifetime history of depression were more likely to have symptoms suggestive of depression before operation and at both postoperative time points. Of the patients with depressive symptoms on POD3 and POD30, 51% and 49%, respectively, had no history of depression or depressive symptoms (Supplementary Tables S5 and S6 ).
Predictors of the severity of postoperative depressive symptoms
Preoperative history of major depression and active preoperative depression symptoms were the only consistent independent predictors of depressive symptom severity at POD3 and POD30, based on both the actual and imputed data (Supplementary Tables S7 and S8) .
Discussion
This multicentre, international, randomised controlled trial found that, in the early postoperative period, there is an approximately 70% increase in the number of patients !60 yr old who report symptoms suggestive of depression and an increase in the severity of depressive symptoms. Ketamine, which has repeatedly been demonstrated to decrease depressive symptoms in numerous clinical settings, did not appear to prevent postoperative depression or mitigate depressive symptoms. These surprising negative findings contrast with those of previous randomised trials and subsequent meta-analyses of ketamine and the treatment of depression. Although lifetime history of depression and preoperative symptoms suggestive of depression were the only consistent predictors of symptoms suggestive of depression at POD3 and POD30, the symptoms were new in onset for approximately 50% of the patients reporting them.
The findings related to ketamine did not support our original hypothesis, which was based on clinical trial and metaanalytic data in the psychiatry literature (treatment of depression) and two randomised controlled trials of surgical patients (prevention or mitigation of depressive (11) 24 (11) 32 (14) 21 (9) symptoms). 12, 13 Previous studies with ketamine have typically been conducted in younger outpatients with moderate-tosevere, chronic, and treatment-refractory major depression. 20 It is possible that the mechanism of treating depression is distinct from preventing or mitigating new-onset depressive symptoms in the perioperative period. However, a randomised trial of healthy (ASA physical status 1 or 2) surgical patients receiving subanaesthetic ketamine during induction of anaesthesia did find positive effects on postoperative depressive symptoms. 13 The patients recruited in the PODCAST trial were medically more complex and underwent major surgery that sometimes included postoperative intensive care. As such, the physiologic stresses of the perioperative period were likely more profound, which might make associated depressive symptoms harder to prevent. Neurobiologically, it should be appreciated that the administration of subanaesthetic ketamine during general anaesthesia represents a radically different neurochemical milieu compared with the waking state. Although the precise mechanism of ketamine's anti-depressant effects is unknown, 21, 22 preclinical studies suggest a role for changes in glutamatergic receptor subtype, 23 ,24 effects on presynaptic Table 2 Preoperative health conditions by PODCAST group assignments. Data are N (%) or n (%) unless otherwise indicated. IQR, interquartile range; PHQ, Patient Health Questionnaire 8; Lo-K, randomised group of patients who received a low dose of ketamine (0.5 mg kg À1 ); Hi-K, randomised group of patients who received a higher dose of ketamine (1 mg kg HCN1 channels, 25 neural trophic factors, 26 and, possibly, functional network reorganisation. 27 Ketamine's metabolites might also exert anti-depressant effects that are not mediated through the N-methyl-D-aspartate (NMDA) glutamate receptor, 28 a major target of the drug. Neurophysiologically, NMDAreceptor antagonists such as ketamine preferentially inhibit gamma-aminobutyric acid interneurones, which normally function as an inhibitory feedback mechanism for excitatory pyramidal cells in the cortex. 29 However, these neurochemical and neurophysiologic factors are profoundly altered in the anaesthetised state. There is evidence for differential effects of ketamine in the cortex when given alone vs during general anaesthesia with another drug. For example, when ketamine is administered as a single drug, it increases high-frequency oscillations and cholinergic tone at subanaesthetic concentrations. 30 However, when subanaesthetic ketamine is administered during isoflurane anaesthesia, cortical acetylcholine levels and high-frequency power remain suppressed. 31 On the subcortical level, mechanisms for ketamine's anti-depressant effects have recently been identified. The NMDA antagonist effects of ketamine suppress burst firing in the lateral habenula; this action might account for its rapid therapeutic efficacy in treating depression. 32 However, recent work has also shown that excitation of glutamatergic neurones in the lateral habenula, which is metabolically activated by many anaesthetics, 33 is critical for propofol sedation and unconsciousness. 34 Thus, administration of ketamine during prolonged general anaesthesiadas was studied in the PODCAST trialdmight create unfavourable neural conditions for anti-depressant effects at both cortical and subcortical levels.
Strengths and limitations
Strengths of this analysis include a dataset from a large, international, pragmatic trial, with two doses of ketamine tested and two postoperative time points assessed. The major limitation is that the PODCAST trial was primarily designed to determine the effect of intraoperative ketamine on postoperative delirium and pain (which did not differ across the treatment arms), and the outcome of depressive symptoms was secondary. It is possible that this study was too small to detect a clinically meaningful beneficial effect of intraoperative ketamine on the proportion of patients suffering from postoperative depression or on postoperative depressive symptoms. A study of 2400 patients (with a ketamine/control patients ratio of 2:1) would have >80% power to detect a decrease in postoperative depression from 15% to 10% (twosided alpha <0.005). Thus, a follow-up study of approximately 3000 patients (to allow for missing follow-up depression assessments) is indicated to address with greater precision and power whether ketamine prevents postoperative depression and improves depressive symptoms. Missing PHQ-8 assessments (i.e. missing outcomes data) was a further major constraint of this study. We attempted to address this with sensitivity analyses using imputed values from previously completed PHQ-8 questionnaires. There are limitations to imputation, but a conservative carry-forward technique was selected. Unlike past studies of psychiatric patients with diagnoses of depression, only 64 patients across the three interventional arms of the trial met screening criteria for depression at baseline. As such, there were insufficient numbers to assess whether ketamine had a curative effect on pre-existing depression as opposed to the preventative effect that was tested in the remaining 606 patients who did not meet screening criteria for depression at baseline. Future studies could focus on surgical patients who all have a preoperative diagnosis of depression. Additionally, ketamine was administered as a single bolus before surgical incision as opposed to a continuous infusion, which is the mode of administration in psychiatric patients. This difference could potentially have an impact on the neurobiological effects of ketamine.
It should be noted that some symptoms of depression on POD3dsuch as diminished interest in activities, altered appetite, confusion, or sleep problemsdmight constitute expected outcomes of major surgery under general anaesthesia. However, new-onset depressive symptoms were also observed at POD30 and, independently of their surgical or pharmacological aetiology, depressive symptoms in the early postoperative period might still be distressing for patients and have a functional impact on recovery. Additional limitations of this study include the self-report technique of assessing depression, which can create bias compared with semistructured interviews or clinical assessment; lack of assessment of other psychiatric conditions, which could influence findings; and exclusive focus on older adults undergoing major surgery, which limits generalised conclusions about the effects of ketamine on postoperative depression.
Conclusion
In conclusion, intraoperative administration of subanaesthetic ketamine might not prevent depression or decrease depressive symptoms after major surgery in patients !60 yr old. Further research is required to reproduce or contradict these negative findings and to clarify whether or not ketamine might be efficacious in a subgroup of surgical patients, such as those with preoperative depression. Given the likely high incidence of new-onset postoperative depression, with negative attendant consequences on recovery, there is an urgent need to discover effective preventive interventions.
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